Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention

被引：12

作者：

Latinovic, Olga ^{[1
]}

Le, Nhut ^{[1
]}

Reitz, Marvin ^{[1
]}

Pal, Ranajit ^{[2
]}

DeVico, Anthony ^{[1
]}

Foulke, James S. ^{[1
]}

Redfield, Robert R. ^{[1
]}

Heredia, Alonso ^{[1
]}

机构：

[1] Univ Maryland, Inst Human Virol, Sch Med, Baltimore, MD 21201 USA

[2] Adv BioSci Labs Inc, Kensington, MD USA

来源：

AIDS | 2011年 / 25卷 / 09期

关键词：

IMMUNODEFICIENCY-VIRUS TYPE-1; SMALL-MOLECULE; MONOCLONAL-ANTIBODY; ANTIVIRAL ACTIVITY; RESISTANT HIV-1; INFECTED ADULTS; PRO; 140; ENTRY; POTENT; ANTAGONISTS;

D O I：

10.1097/QAD.0b013e3283471edb

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

CCR5 blockers inhibit CCR5-tropic (R5) HIV-1, including strains resistant to other antiretrovirals. We demonstrate that the CCR5 antibody HGS004 and the CCR5 antagonist maraviroc have potent antiviral synergy against R5 HIV-1, translating into dose reductions of more than 10-fold for maraviroc and more than 150-fold for HGS004. These data, together with the high barrier of resistance to HGS004, suggest that combinations of maraviroc and HGS004 could provide effective preventive and therapeutic strategies against R5 HIV-1.

引用

页码：1232 / 1235

页数：4

共 23 条

[1] QUANTITATIVE-ANALYSIS OF DOSE-EFFECT RELATIONSHIPS - THE COMBINED EFFECTS OF MULTIPLE-DRUGS OR ENZYME-INHIBITORS [J].

CHOU, TC ;

TALALAY, P .

ADVANCES IN ENZYME REGULATION, 1984, 22 :27-55

[2] Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity [J].

Dorr, P ;

Westby, M ;

Dobbs, S ;

Griffin, P ;

Irvine, B ;

Macartney, M ;

Mori, J ;

Rickett, G ;

Smith-Burchnell, C ;

Napier, C ;

Webster, R ;

Armour, D ;

Price, D ;

Stammen, B ;

Wood, A ;

Perros, M .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (11) :4721-4732

[3]

FDA notifications, 2007, AIDS ALERT, V22, P103

[4]

GIGUEL F, 2006, 13 C RETR OPP INF 5

[5] Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1 [J].

Heredia, Alonso ;

Latinovic, Olga ;

Gallo, Robert C. ;

Melikyan, Gregory ;

Reitz, Marv ;

Le, Nhut ;

Redfield, Robert R. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (51) :20476-20481

[6] HIV entry: new insights and implications for patient management [J].

Hughes, Amelia ;

Nelson, Mark .

CURRENT OPINION IN INFECTIOUS DISEASES, 2009, 22 (01) :35-42

[7] Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults [J].

Jacobson, Jeffrey M. ;

Saag, Michael S. ;

Thompson, Melanie A. ;

Fischl, Margaret A. ;

Liporace, Ralph ;

Reichman, Richard C. ;

Redfield, Robert R. ;

Fichtenbaum, Carl J. ;

Zingman, Barry S. ;

Patel, Mahesh C. ;

Murga, Jose D. ;

Pemrick, Suzanne M. ;

D'Ambrosio, Paul ;

Michael, Marti ;

Kroger, Hans ;

Ly, Hieu ;

Rotshteyn, Yakov ;

Buice, Robert ;

Morris, Stephen A. ;

Stavola, Joseph J. ;

Maddon, Paul J. ;

Kremer, Alton B. ;

Olson, William C. .

JOURNAL OF INFECTIOUS DISEASES, 2008, 198 (09) :1345-1352

[8] Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults [J].

Jacobson, Jeffrey M. ;

Lalezari, Jacob P. ;

Thompson, Melanie A. ;

Fichtenbaum, Carl J. ;

Saag, Michael S. ;

Zingman, Barry S. ;

D'Ambrosio, Paul ;

Stambler, Nancy ;

Rotshteyn, Yakov ;

Marozsan, Andre J. ;

Maddon, Paul J. ;

Morris, Stephen A. ;

Olson, William C. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (10) :4137-4142

[9] Anti-HIV-1 Activity of Weekly or Biweekly Treatment with Subcutaneous PRO 140, a CCR5 Monoclonal Antibody [J].

Jacobson, Jeffrey M. ;

Thompson, Melanie A. ;

Lalezari, Jacob P. ;

Saag, Michael S. ;

Zingman, Barry S. ;

D'Ambrosio, Paul ;

Stambler, Nancy ;

Rotshteyn, Yakov ;

Marozsan, Andre J. ;

Maddon, Paul J. ;

Morris, Stephen A. ;

Olson, William C. .

JOURNAL OF INFECTIOUS DISEASES, 2010, 201 (10) :1481-1487

[10] CCR5 small-molecule antagonists and monoclonal antibodies exert potent synergistic antiviral effects by cobinding to the receptor [J].

Ji, Changhua ;

Zhang, Jun ;

Dioszegi, Marianna ;

Chiu, Sophie ;

Rao, Eileen ;

deRosier, Andre ;

Cammack, Nick ;

Brandt, Michael ;

Sankuratri, Surya .

MOLECULAR PHARMACOLOGY, 2007, 72 (01) :18-28

← 1 2 3 →